Synairgen PLC (LON:SNG) target price held steady at 137.00GBX, reported today by finnCap
- Updated: November 29, 2016
Synairgen PLC (LON:SNG) had its target price hold steady to 137.00GBX by finnCap in a report released 11/29/2016. The new target price indicates a possible upside of 8.45% based on the company's last stock close price.
Previously on Thursday January 28, 2016, N+1 Singer reported about Synairgen PLC (LON:SNG) held steady the target price at 47.00GBX. At the time, this indicated a possible upside of 0.92%.
Yesterday Synairgen PLC (LON:SNG) traded -3.38% lower at 14.50GBX. The company’s 50-day moving average is 18.81GBX and its 200-day moving average is 28.20GBX. The last stock close price is down -50.31% from the 200-day moving average, compared to the S&P 500 which has decreased -0.03% over the same time. 5,000 shares of the stock were exchanged, down from an average trading volume of 102,321
See Chart Below
Synairgen PLC has a 52 week low of 14.01GBX and a 52 week high of 38.00GBX The company’s market cap is currently 0 GBX.
In addition to finnCap reporting its target price, a total of 2 firms have reported on the stock. The consensus target price is 87.00GBX with 0 firms rating the stock a strong buy, 1 firm rating the stock a buy, 0 firms rating the stock a hold, 0 firms rating the stock a underperform, and finally 0 firms rating the stock a sell.
About Synairgen PLC (LON:SNG)
Synairgen plc is a holding company. The Company is engaged in the drug discovery and development of therapies for respiratory diseases, particularly in the areas, including severe asthma, chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis (IPF). The Company uses its human biology BioBank platform to discover and develop therapies for respiratory disease. Using the BioBank platform, it has developed a number of tissue models, which include In vitro and Ex vivo models. The Company's primary asset is AZD9412, which is an inhaled interferon beta (IFN-beta) therapy. AZD9412 is outlicensed to AstraZeneca for the clinical development and commercialization, and is in a confirmatory Phase II trial. Its drug programs include IFN-b (SNG001) for Asthma and COPD, and Lysyl oxidase-like protein 2 (LOXL2) inhibitors for IPF. The Company's subsidiary includes Synairgen Research Limited, which is engaged in the drug discovery and development.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.